IBIO - iBio and AstralBio Advance Novel Obesity Therapy with Promising Early Results

2025-06-24 15:00:54 ET

iBio, Inc. ( IBIO ) is pushing deeper into the obesity treatment race with its partner AstralBio, unveiling compelling preclinical data for a new antibody-based therapy that targets the amylin receptor . This program focuses on a novel approach to help regulate appetite and body weight, showing reductions in food intake comparable to leading experimental peptide-based drugs.

In a study using obese mice, the engineered antibody demonstrated a 60 percent drop in food consumption, closely matching the performance of a well-known dual-action peptide therapy. This promising result gives early validation to the potential of amylin receptor agonist antibodies, which may offer longer-lasting and more tolerable treatment options for obesity and related metabolic conditions.

Unlike existing therapies that often rely on peptide compounds, iBio's approach uses antibodies designed to act only on amylin receptors while avoiding the calcitonin receptor, which is commonly targeted in other treatments. This selective targeting is aimed at improving tolerability without sacrificing the efficacy observed in earlier dual-agonist drugs.

The amylin receptor plays a key role in hunger regulation by helping to prolong feelings of fullness and slow digestion. By harnessing AI and its proprietary drug discovery technology, iBio has developed antibodies that can fine-tune this response more precisely than traditional compounds. The goal is to achieve significant weight loss while minimizing side effects and preserving lean muscle mass.

With this latest amylin program, iBio adds a third asset to its growing portfolio in partnership with AstralBio.

Shares of IBIO are up 22.81% today following the announcement.

The post iBio and AstralBio Advance Novel Obesity Therapy with Promising Early Results appeared first on PRISM MarketView .

COMTEX_466630884/2927/2025-06-24T14:00:54